AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16483027 — intervention group
Group type: COMPARATOR
Intervention: Refined sunflower oil
Number of subjects: 14
Study 12072043 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen supplementation (oestradiol valerate 1 mg daily, n = 7)
Number of subjects: 12
Study 12072043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 12
Study 9164902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachectic heart failure patients
Number of subjects: 79
Study 9164902 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncachectic heart failure patients
Number of subjects: 79
Study 9164902 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 79
Study 1841609 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 3000
Study 1841609 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3000
Study 7131001 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine and horizontal position
Number of subjects: 76
Study 7131001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone and horizontal position
Number of subjects: 76
Study 7131001 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine with head-down tilt position
Number of subjects: 76
Study 7131001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone with head-down tilt position
Number of subjects: 76
Study 29775119 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise program
Number of subjects: 30
Study 29775119 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow stem cell transplantation (ABMSCT)
Number of subjects: 30
Study 29775119 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy and diabetic diet regime
Number of subjects: 30
Study 28017455 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological counselling and prolonged follow-up for at least 4 weeks after discharge
Number of subjects: 0
Study 25182045 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy for 6 months
Number of subjects: 391
Study 25182045 — intervention group
Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 391
Study 25208464 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (100 mg subcutaneously every 4 weeks for three doses, then every 8 weeks for five doses over 48 weeks)
Number of subjects: 101
Study 25208464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 25208464 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 101
Study 22764762 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 0
Study 22764762 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exemestane
Number of subjects: 0
Study 19354088 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (2.0 mg intramuscularly) at rest (T1)
Number of subjects: 7
Study 19354088 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo before 90 minutes of intermittent exercise (T2)
Number of subjects: 7
Study 19354088 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine before 90 minutes of intermittent exercise (T3)
Number of subjects: 7
Study 17239866 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG-triggered ovulation
Number of subjects: 0
Study 17239866 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ovulation
Number of subjects: 0
Study 15053783 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 66
Study 15053783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 11356434 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg, increased to a maximum of 25 mg twice daily
Number of subjects: 1959
Study 11356434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959
Study 11356434 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959
Study 9879871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood hyperkalaemic cardioplegia with magnesium
Number of subjects: 23
Study 9879871 — intervention group
Group type: COMPARATOR
Intervention: Intermittent antegrade warm blood hyperkalaemic cardioplegia only
Number of subjects: 23
Study 7802299 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion at incremental rates (30, 60, and 120 micrograms.kg‐1.min‐1)
Number of subjects: 20
Study 2388132 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-elemental formula (Group A)
Number of subjects: 90
Study 2388132 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing soy proteins and vegetable oils (Group B)
Number of subjects: 90
Study 2388132 — intervention group
Group type: COMPARATOR
Intervention: Common cow's-milk formula (Group C)
Number of subjects: 90
Study 2388132 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A and B (after 4 weeks challenge with cow's milk)
Number of subjects: 90
Study 466336 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutter treatment for ingrowing toenails
Number of subjects: 61
Study 466336 — intervention group
Group type: COMPARATOR
Intervention: Wedge resection procedure
Number of subjects: 61
Study 466336 — intervention group
Group type: COMPARATOR
Intervention: Toenail avulsion
Number of subjects: 61
Study 30592144 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcast videos on airway management
Number of subjects: 34
Study 30592144 — intervention group
Group type: COMPARATOR
Intervention: Conventional one-to-one hands-on training
Number of subjects: 34
Study 28992899 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive-behavioral therapy (CBT) plus three therapist support calls
Number of subjects: 25
Study 28992899 — intervention group
Group type: COMPARATOR
Intervention: Online cognitive-behavioral therapy (CBT) without therapist support calls
Number of subjects: 25
Study 25882864 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction through 6 months hypocaloric dieting
Number of subjects: 0
Study 25882864 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 25882864 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 25882864 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide receptor type C mRNA expression
Number of subjects: 0
Study 25882864 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide receptor type A mRNA expression
Number of subjects: 0
Study 24062325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Bodies (BB) Healthy Lifestyle Program
Number of subjects: 0
Study 24062325 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (CC)
Number of subjects: 0
Study 20864417 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (90-minute infusion)
Number of subjects: 0
Study 20864417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 0
Study 20864417 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1-time bolus)
Number of subjects: 0
Study 19407805 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin at bedtime (100 mg/day)
Number of subjects: 244
Study 19407805 — intervention group
Group type: COMPARATOR
Intervention: Aspirin on awakening (100 mg/day)
Number of subjects: 244
Study 19407805 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacological hygienic-dietary recommendations
Number of subjects: 244
Study 17606561 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (12 U/kg)
Number of subjects: 33
Study 17606561 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injections
Number of subjects: 33
Study 15128894 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin (100 mg/m² on days 1, 22, and 43) with radiotherapy (66 Gy over 6.5 weeks)
Number of subjects: 334
Study 15128894 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (66 Gy over 6.5 weeks)
Number of subjects: 334
Study 15128894 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin with radiotherapy
Number of subjects: 334
Study 15128894 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 334
Study 11922401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg, 20 mg, 30 mg
Number of subjects: 10
Study 11922401 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine 10 mg
Number of subjects: 10
Study 11922401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 30 mg
Number of subjects: 10
Study 9620515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 20
Study 9620515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10087864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent confidence in two hypotheses
Number of subjects: 0
Study 10087864 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraging consideration of the alternative
Number of subjects: 0
Study 10087864 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent confidence with intervention to produce complementarity
Number of subjects: 0
Study 10087864 — intervention group
Group type: COMPARATOR
Intervention: Independent confidence without intervention
Number of subjects: 0
Study 2752891 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glucose tolerance (IGT and diabetes)
Number of subjects: 1422
Study 2752891 — intervention group
Group type: EXPERIMENTAL
Intervention: IGT
Number of subjects: 1422
Study 2752891 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1422
Study 2752891 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemics
Number of subjects: 1422
Study 2752891 — intervention group
Group type: COMPARATOR
Intervention: IGTs
Number of subjects: 1422
Study 2752891 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial IGTs
Number of subjects: 1422
Study 2752891 — intervention group
Group type: COMPARATOR
Intervention: Initial normoglycaemics
Number of subjects: 1422
Study 2752891 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of worsening glucose tolerance
Number of subjects: 1422
Study 320827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine (70 mg t.i.d.)
Number of subjects: 62
Study 320827 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (50 mg t.i.d.)
Number of subjects: 62
Study 31399845 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100/300 mg once daily)
Number of subjects: 10142
Study 31399845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 28007971 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational tool (spiral-bound, laminated booklet with safety messages), plug-in CO detector, and 9V battery
Number of subjects: 299
Study 28007971 — intervention group
Group type: COMPARATOR
Intervention: One page flyer on CO poisoning prevention
Number of subjects: 299
Study 26844281 — intervention group
Group type: EXPERIMENTAL
Intervention: R213G heterozygotes (213RG)
Number of subjects: 4498
Study 26844281 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic subjects
Number of subjects: 4498
Study 23790987 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigmatizing campaigns
Number of subjects: 1085
Study 23790987 — intervention group
Group type: COMPARATOR
Intervention: Neutral campaigns
Number of subjects: 1085
Study 21448363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with fluorouracil plus cisplatin (PCF)
Number of subjects: 94
Study 21448363 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin combined with fluorouracil plus leucovorin (FOLFOX‐4)
Number of subjects: 94
Study 19335936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous synthetic THC (2.5 mg)
Number of subjects: 22
Study 19335936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16750125 — intervention group
Group type: EXPERIMENTAL
Intervention: One drug taken at bedtime
Number of subjects: 123
Study 16750125 — intervention group
Group type: COMPARATOR
Intervention: All drugs taken in the morning
Number of subjects: 123
Study 15280529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive treatment (angioplasty and/or open surgery)
Number of subjects: 79
Study 15280529 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring and intervention based on clinical criteria (control group)
Number of subjects: 79
Study 11315820 — intervention group
Group type: COMPARATOR
Intervention: LP 100%
Number of subjects: 8
Study 11315820 — intervention group
Group type: EXPERIMENTAL
Intervention: LP 50%
Number of subjects: 8
Study 11315820 — intervention group
Group type: EXPERIMENTAL
Intervention: LP 75%
Number of subjects: 8
Study 11315820 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in premeal insulin dose
Number of subjects: 8
Study 9134643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity coumarin therapy
Number of subjects: 10
Study 9134643 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity coumarin therapy
Number of subjects: 10
Study 8185424 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg/d
Number of subjects: 31
Study 8185424 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 1.25 mg/d
Number of subjects: 31
Study 8185424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3408013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioclusive transparent polyurethane (TP) dressing
Number of subjects: 598
Study 3408013 — intervention group
Group type: COMPARATOR
Intervention: Cotton gauze (CG) dressing
Number of subjects: 598
Study 31758164 — intervention group
Group type: EXPERIMENTAL
Intervention: High milk intake
Number of subjects: 0
Study 31758164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soft drink intake
Number of subjects: 0
Study 31758164 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncaloric soft drink intake
Number of subjects: 0
Study 31758164 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26291918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% DHEA (prasterone) ovules administered intravaginally daily for 12 weeks
Number of subjects: 0
Study 23599120 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 to 12 mg kg(‐1) per day of iron supplementation based on the ZnPP/H
Number of subjects: 81
Study 23599120 — intervention group
Group type: COMPARATOR
Intervention: 2.2 mg kg(‐1) per day of ferrous sulfate (control)
Number of subjects: 81
Study 21883322 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 2 g tds
Number of subjects: 115
Study 21883322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 19214545 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ovarian drilling
Number of subjects: 44
Study 19214545 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ovarian drilling
Number of subjects: 44
Study 16463240 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly motivated group
Number of subjects: 64
Study 16463240 — intervention group
Group type: COMPARATOR
Intervention: Minimally motivated group
Number of subjects: 64
Study 15343198 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interview (MI)
Number of subjects: 152
Study 15343198 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 152
Study 10789748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging
Number of subjects: 52
Study 10789748 — intervention group
Group type: COMPARATOR
Intervention: Surgical exploration
Number of subjects: 52
Study 10168262 — intervention group
Group type: EXPERIMENTAL
Intervention: Supermarket intervention including flyers, coupons, and signage
Number of subjects: 960
Study 10168262 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 960
Study 8230988 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) administered intravenously (dose 100 m/kg b.w.)
Number of subjects: 100
Study 8230988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MgSO4)
Number of subjects: 100
Study 3633631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme therapy
Number of subjects: 20
Study 3633631 — intervention group
Group type: COMPARATOR
Intervention: Control (no pancreatic enzyme therapy)
Number of subjects: 20
Study 31682878 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-VAP patients receiving early adequate therapy (n=70, 68.6%)
Number of subjects: 102
Study 31682878 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-VAP patients
Number of subjects: 102
Study 31682878 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for Day-30 mortality
Number of subjects: 102
Study 31682878 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate treatment (monotherapy or combination of antimicrobials)
Number of subjects: 102
Study 29635119 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving
Number of subjects: 120
Study 29635119 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition
Number of subjects: 120
Study 29635119 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 26803589 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (carbohydrate <40 g/day)
Number of subjects: 148
Study 26803589 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (<30% energy from fat, <7% from saturated fat)
Number of subjects: 148
Study 26803589 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 148
Study 24881463 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian suppression
Number of subjects: 4690
Study 24881463 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus ovarian suppression
Number of subjects: 4690
Study 22237064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 737
Study 22237064 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 737
Study 20051257 — intervention group
Group type: EXPERIMENTAL
Intervention: Wujijing Oral Liquid (WJJ) 10mL twice daily for 2 menstrual cycles
Number of subjects: 53
Study 20051257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 18038179 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser therapy (810 nm)
Number of subjects: 7
Study 18038179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) therapy
Number of subjects: 7
Study 18038179 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 7
Study 16395994 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 16395994 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 12759802 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 49
Study 12759802 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 49
Study 12759802 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 49
Study 12759802 — intervention group
Group type: EXPERIMENTAL
Intervention: All antipsychotic medications
Number of subjects: 49
Study 10553856 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg succinylcholine
Number of subjects: 50
Study 10553856 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg succinylcholine
Number of subjects: 50
Study 8688343 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pastilles containing amphotericin, polymyxin and tobramycin, suck four times daily
Number of subjects: 275
Study 8688343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 12797050 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 650
Study 12797050 — intervention group
Group type: COMPARATOR
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 650
Study 6823893 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day record (7DR)
Number of subjects: 40
Study 6823893 — intervention group
Group type: COMPARATOR
Intervention: 3-day record (3DR)
Number of subjects: 40
Study 6823893 — intervention group
Group type: COMPARATOR
Intervention: 1-day record (1DR)
Number of subjects: 40
Study 6823893 — intervention group
Group type: COMPARATOR
Intervention: Food frequency form
Number of subjects: 40
Study 31039165 — intervention group
Group type: COMPARATOR
Intervention: Facility-based screening (sputum Xpert MTB/RIF performed on all patients with TB symptoms)
Number of subjects: 3755
Study 31039165 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact tracing (household tracing and monetary incentives for screening contacts of TB patients)
Number of subjects: 3755
Study 30206197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage (2 times for 5 minutes each)
Number of subjects: 60
Study 30206197 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing interventions
Number of subjects: 60
Study 25864623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (vitamin D3 [cholecalciferol], 2000 IU/d)
Number of subjects: 25875
Study 25864623 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids (Omacor(®) fish oil, 1 g/d)
Number of subjects: 25875
Study 25864623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both vitamin D and omega-3)
Number of subjects: 25875
Study 24196538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl suture
Number of subjects: 70
Study 24196538 — intervention group
Group type: COMPARATOR
Intervention: Titanium tacker
Number of subjects: 70
Study 21987240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin 400 mg
Number of subjects: 12
Study 21987240 — intervention group
Group type: COMPARATOR
Intervention: Intravenous moxifloxacin 400 mg
Number of subjects: 12
Study 20541286 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine algorithm using combined brain imaging and biomarkers
Number of subjects: 737
Study 17141357 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin and vinorelbine
Number of subjects: 482
Study 17141357 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study 15905296 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/day)
Number of subjects: 118